


**Figure 2.** Denaturing PAGE gel (20%) of primer–template elongation products obtained with HIV-1 reverse transcriptase at 37 °C for 60 min. A) Abasic site template; B) 1NPE-protected template; enzyme concentrations 0.5 and 2.0 units. Ref: without enzyme and dNTPs. A, T, G, C: reactions in presence of the corresponding dNTPs; N: reactions in presence of all four dNTPs; Nat: unmodified template (X=U) and all four dNTPs.

posite the abasic lesion. Qualitatively, the dNTPs are incorporated in the order  $A > G > T \approx C$ . Some exonuclease activity is observed on the primer strand in the case of (slow) pyrimidine-nucleotide incorporation.

We also tested the template strand that contained the protected abasic residue (Figure 2B) for dNTP incorporation by HIV-1 reverse transcriptase. This experiment was performed so as to determine the difference between an abasic site and a noncoding, non-hydrogen bonding, stereochemically demanding base replacement. In contrast to the situation at the abasic site, essentially no dNTP incorporation was observed at low enzyme concentration. Incorporation and full-length extension were observed only at fourfold higher enzyme concentration. Again, dA was preferentially introduced opposite the bulky 1NPE group, while the other three dNTPs were incorporated at substantially slower rates.

We also checked for the RNase H activity of HIV-1 reverse transcriptase. For this, the abasic (X=AS) and unmodified (X=

U) template strands were  $^{32}\text{P}$  5'-end labeled and the primer was not labeled (Figure 3).



**Figure 3.** RNase H activity of HIV-1 reverse transcriptase on primer–template complexes that either contained the unmodified template (X=U) or the RNA abasic site (X=AS). Experimental conditions were the same as those used for primer-elongation experiments. HIV-1 reverse transcriptase (RT) concentrations are indicated.

Control experiments performed in the absence of HIV-1 reverse transcriptase (Figure 3, left 2 lanes) show that the RNA template is partially cleaved at the abasic site, presumably by  $\beta$ -elimination at the 3' terminus of the RNA. We assume, however, that most of this cleavage occurs under denaturation conditions (5 min, 90 °C) prior to application to the gel and not during incubation. We note that partial cleavage is not expected to interfere with primer extension as the RNA template is used in excess. At low enzyme concentration essentially no RNase H activity is observed. Increasing the enzyme concentration to 2 units results in complete disappearance of the full-length RNA template. Interestingly, there are differences in the RNA degradation pattern as a function of the presence or absence of the RNA abasic site. In the unmodified RNA template, cleavage occurs predominantly at the junction between the double-helical part and the RNA single strand. However, in the abasic template, cleavage is effected predominantly in the double helical primer–template region. This differential cleavage pattern is in accord with the enzyme predominantly cleaving in the unextended primer part due to slow elongation in the latter case.

We draw the following conclusions from these preliminary results: phosphoramidite **1** is a useful building block for the synthesis of abasic RNA. It is readily incorporated by conventional RNA solid-phase synthesis, and the 1NPE group is almost quantitatively cleaved after 1 min of irradiation with a UV immersion lamp. Furthermore, an RNA abasic site is readily by-

passed by HIV-1 reverse transcriptase. As in the case of DNA templates,<sup>[11]</sup> a deoxyadenosine residue is preferentially introduced opposite the abasic site; this demonstrates that the "A rule"<sup>[12]</sup> is also valid when the template is an abasic RNA strand. In addition, RNase H activity is not inhibited by the presence of an abasic site. Work towards a comprehensive kinetic characterization of reverse transcriptase action on abasic RNA templates is currently underway.

The study of the biological role of abasic RNA has so far been hampered by the lack of a reliable method for its synthesis. With this technique at hand it might now become possible to incorporate such lesions into larger, biologically relevant RNA molecules by, for example, splint ligation methods.<sup>[13]</sup> The study of such constructs will be of interest, for instance, in the context of RNA viral evolution, rRNA function, mRNA translation, and of a possible existence of an RNA repair mechanism.

## Experimental Section

**Synthesis, deprotection, and purification of oligonucleotides:** All oligonucleotides were prepared by automated oligonucleotide synthesis with an Expedite 8900 nucleic-acid synthesis system (PerSeptive Biosystems, Inc., Framingham, MA) by using the cyanoethylphosphoramidite approach. For RNA synthesis 2'-O-TBDMS protected PAC-phosphoramidites (GlenResearch) and polystyrene solid supports (Amersham Biotech) were used. For DNA synthesis benzoyl (dA, dC) and isobutyryl (dG) protected phosphoramidites and controlled pore-glass solid supports (GlenResearch) were used. The synthesis was performed by using the same standard coupling protocol for DNA and RNA with 5-(ethylthio)-1H-tetrazole (Aldrich) as activator and a coupling time of 90 s for DNA and 6 min for RNA. The modified phosphoramidite was allowed to couple for 12 min. Solid supports were treated with EtOH/NH<sub>4</sub>OH (1:4) at 55 °C, overnight. RNA sequences were further deprotected by treatment with Bu<sub>4</sub>NF (1 M in THF) for 6 h at RT. Oligonucleotides were desalted by using Sep-Pak<sup>®</sup> C<sub>18</sub> columns (Waters, Milford, MA) before application to HPLC.

The DNA primer for the primer-template extension reactions and the RNA heptamer were purified by using RP-HPLC on an ÄKTA 900 HPLC system (Amersham Pharmacia Biotech). A Brownlee Aquapore RP-300 (C<sub>8</sub>, 7 µm, 250/4.6 mm) column (PerkinElmer) was used with a gradient of solvent A (0.1 M Et<sub>3</sub>NOAc in H<sub>2</sub>O, pH 7.0) and solvent B (0.1 M Et<sub>3</sub>NOAc, CH<sub>3</sub>CN/H<sub>2</sub>O (4:1)). The 31-mer RNA templates were purified on a 20% preparative denaturing (7 M urea) polyacrylamide gel. The oligoribonucleotides were then electroeluted with an Elutrap<sup>®</sup> electroelution system (Schleicher & Schuell) according to the manufacturer's protocol and desalted by using Sep-Pak<sup>®</sup> C<sub>18</sub> columns. Purified oligonucleotides were dissolved in DEPC-treated water and the concentration was determined by using a NanoDrop<sup>®</sup> ND-100 UV/Vis spectrophotometer (NanoDrop Technologies, Inc., Wilmington, DE).

**Kinetics of 1NPE deprotection:** 1NPE-protected oligonucleotides were deprotected at RT by using a UV immersion lamp TQ 150 (UV-RS-2, Heraeus). Aliquots (0.4 mL) of a 1 OD<sub>260</sub> mL<sup>-1</sup> solution of 1NPE-protected RNA heptamer **2** were exposed to UV light for different time intervals in a quartz cuvette and immediately analyzed by RP-HPLC. The ratio of **2**:**3** was determined by peak integration. From the first order rate law for disappearance of **2** we calculated a deprotection extent of > 99.99% after irradiation for 2 min. Inte-

gration of ESI-MS peaks at the *m/z* of **2** and **3** confirmed this result and showed a deprotection extent of > 99% after 2 min.

**HIV-1 reverse transcriptase assays:** HIV-1 reverse transcriptase (Worthington Biochemical Corporation, Lakewood, NJ) was diluted in storage buffer (10 mM K<sub>3</sub>PO<sub>4</sub>, pH 7.4, 1 mM DTT, 20% glycerol). For the primer-extension experiments the DNA primer (30 pmol) was labeled by using T4-polynucleotide kinase (10 units, Fermentas) and [ $\gamma$ -<sup>32</sup>P]ATP (Hartmann Analytik GmbH, Braunschweig, Germany) in T4 buffer (50 mM Tris-HCl pH 7.6, 10 mM MgCl<sub>2</sub>, 5 mM DTT, 0.1 mM spermidine, 0.1 mM EDTA) for 30 min at 37 °C. T4-Polynucleotide kinase was then inactivated by heating to 90 °C for 2 min. For the RNase H assay the RNA templates (X=U or 1NPE) were 5'-end labeled as described above and used together with unlabeled DNA primer. The 1NPE-protected RNA template and DNA primer were annealed in a molar ratio of 2:1 in HIV-1 reverse transcriptase buffer. For the assays with abasic RNA this mixture was irradiated with a UV lamp for 2 min as described before. Final reaction mixtures contained RNA template (100 nM), DNA primer (50 nM), and dNTP (20 µM) in buffer (50 mM Tris pH 8.3, 50 mM NaCl, 8 mM MgCl<sub>2</sub>, 1 mM DTT). After addition of the enzyme the mixtures were incubated for 60 min at 37 °C. The reactions were then quenched with loading buffer (98% formamide, 0.1% xylene cyanol (FF), 0.1% bromophenol blue), heated to 90 °C for 5 min and applied to a denaturing PAGE gel (20%). Radioactivity was detected and quantified on a Storm 820 Phosphorimager with ImageQuant software (Amersham Biosciences).

## Acknowledgements

The authors wish to thank Dr. Caroline Crey-Desbiolles for valuable experimental advice on the primer-template elongation experiments. Financial support from the Swiss National Science Foundation (grant No.: 200020-107692) is gratefully acknowledged.

**Keywords:** abasic sites • bioorganic chemistry • nucleic acids • RNA damage • RNA

- [1] J. Lhomme, J. F. Constant, M. Demeunynck, *Biopolymers* **1999**, *52*, 65–83.
- [2] O. D. Schärer, *Angew. Chem.* **2003**, *115*, 3052–3082; *Angew. Chem. Int. Ed.* **2003**, *42*, 2946–2974.
- [3] V. L. Schramm, *Curr. Opin. Chem. Biol.* **1997**, *1*, 323–331.
- [4] T. Ogasawara, T. Sawasaki, R. Morishita, A. Ozawa, K. Madin, Y. Endo, *EMBO J.* **1999**, *18*, 6522–6531.
- [5] P. A. Aas, M. Otterlei, P. O. Falnes, C. B. Vagbo, F. Skorpen, M. Akbari, O. Sundheim, M. Bjoras, G. Slupphaug, E. Seeberg, H. E. Krokan, *Nature* **2003**, *421*, 859–863.
- [6] Y. Nishikawa, B. L. Adams, S. M. Hecht, *J. Am. Chem. Soc.* **1982**, *104*, 326–328.
- [7] J. D. Trzuppek, T. L. Sheppard, *Org. Lett.* **2005**, *7*, 1493–1496.
- [8] S. Pitsch, P. A. Weiss, X. Wu, D. Ackermann, T. Honegger, *Helv. Chim. Acta* **1999**, *82*, 1753–1761.
- [9] S. Pitsch, P. A. Weiss, L. Jenny, A. Stutz, X. Wu, *Helv. Chim. Acta* **2001**, *84*, 3773–3795.
- [10] L. Menendez-Arias, *Prog. Nucleic Acid Res. Mol. Biol.* **2002**, *71*, 91–147.
- [11] H. Cai, L. B. Bloom, R. Eritja, M. F. Goodman, *J. Biol. Chem.* **1993**, *268*, 23567–23572.
- [12] B. S. Strauss, *Bioessays* **1991**, *13*, 79–84.
- [13] M. J. Moore, P. A. Sharp, *Science* **1992**, *256*, 992–997.

Received: May 17, 2005